BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the medical technology company’s stock.

BIOLASE Trading Down 2.2 %

BIOLASE stock opened at $0.15 on Friday. BIOLASE has a 12 month low of $0.13 and a 12 month high of $32.09. The company has a market capitalization of $4.83 million, a price-to-earnings ratio of 0.00 and a beta of 0.71. The business’s fifty day simple moving average is $0.15 and its two-hundred day simple moving average is $0.74. The company has a current ratio of 1.26, a quick ratio of 0.68 and a debt-to-equity ratio of 34.06.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share (EPS) for the quarter. BIOLASE had a negative return on equity of 555.22% and a negative net margin of 41.97%. The firm had revenue of $13.49 million during the quarter.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.